Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBioNTech SE

BioNTech SE

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
87.51 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
690073
Market Cap
28221.88M

Momentum Score

…

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
84.89
Low
87.94
High
52 Week Price Range
79.52
Low
124.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioNTech SE develops mRNA-based vaccines and immunotherapies and is known for its COVID-19 vaccine co-developed with Pfizer. Long-term growth drivers include its mRNA platform applied to oncology and infectious diseases, a broad clinical pipeline, and manufacturing and partner network. It may attract investors seeking exposure to an established mRNA technology with multiple late-stage programs and global commercialization experience.
Material risks include reliance on COVID-19 vaccine revenue, clinical and regulatory setbacks, strong competition in mRNA and oncology, and manufacturing or pricing pressures.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
87.51
Dividend Yield
-
Revenue TTM
2869.90M
Revenue Per Share
11.87
Gross Profit TTM
2258.60M
Debt / Equity
0.01
ROE
-5.88%
Net Debt
-7404.85M
ROCE
-3.14%
Diluted EPS TTM
-5.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1009.33M -677.70M 1186.10M 12954.10M 15046.40M
Minority interest - - - - 0.00M
Net income -1091.26M -665.30M 930.30M 9434.40M 10292.50M
Selling general administrative 588.20M 531.10M 495.00M 484.70M 278.50M
Selling and marketing expenses 110.00M 67.90M 62.70M 59.50M 50.40M
Gross profit 2140.16M 2209.80M 3219.20M 12778.60M 15116.00M
Reconciled depreciation 382.80M 298.00M 183.40M 123.30M 75.20M
Ebit -623.87M -665.10M 972.00M 12642.70M 15283.80M
Ebitda -256.17M -367.10M 1155.40M 13096.30M 14970.70M
Depreciation and amortization 367.69M 298.00M 183.40M 453.60M -313.10M
Operating income -623.87M -1314.30M 690.40M 12642.70M 15283.80M
Other operating expenses 3380.50M 4065.40M 2914.80M 4667.90M 4060.80M
Interest expense 13.64M 13.16M 7.74M 18.90M 5.40M
Tax provision 85.30M -12.40M 255.80M 3519.70M 4753.90M
Interest income - 437.60M 357.60M 330.30M 1.50M
Net interest income -11.10M 425.00M 349.70M 311.40M -25.80M
Income tax expense 81.93M -12.40M 255.80M 3519.70M 4753.90M
Total revenue 2756.63M 2751.10M 3819.00M 17310.60M 18976.70M
Total operating expenses 2764.03M 3524.10M 2315.00M 135.90M 200.10M
Cost of revenue 616.47M 541.30M 599.80M 4532.00M 3860.70M
Total other income expense net -385.46M 636.60M -67.80M 311.40M -237.40M
Net income from continuing ops -1136.10M -665.30M 930.30M 9434.40M 10292.50M
Net income applicable to common shares - - - - 10292.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21979.24M 22529.70M 23006.30M 23279.10M 15830.80M
Intangible assets 1605.32M 790.40M 804.10M 158.50M 144.60M
Other current assets 210.71M 212.70M 280.90M 271.90M 64.90M
Total liab 2763.22M 3118.60M 2760.40M 3223.50M 3937.10M
Total stockholder equity 19216.02M 19411.10M 20245.90M 20055.60M 11893.70M
Deferred long term liab - - - - 13.60M
Other current liab 799.96M 1757.60M 1335.10M 2633.40M 3002.60M
Common stock 258.89M 248.60M 248.60M 248.60M 246.30M
Capital stock 259.00M 248.60M 248.60M 248.60M 246.30M
Retained earnings 17954.26M 19098.00M 19763.30M 18833.00M 9882.90M
Other liab - - - - 283.90M
Good will 367.74M 380.60M 362.50M 61.20M 57.80M
Other assets - - - 249.20M 22.20M
Cash 7672.13M 9761.90M 11663.70M 13875.10M 1692.70M
Total current liabilities 2141.39M 2523.20M 2070.50M 2950.60M 3481.60M
Current deferred revenue 754.58M 294.90M 353.30M 77.10M 189.10M
Net debt -7404.85M -9507.70M -11444.60M -13662.90M -1391.20M
Short term debt 52.18M 39.50M 28.10M 36.00M 129.90M
Short long term debt 52.20M 39.50M 28.10M 36.00M 129.90M
Short long term debt total 267.29M 254.20M 219.10M 212.20M 301.50M
Other stockholder equity 2464.55M 1390.00M 1218.60M -5.30M -3.80M
Property plant equipment - - - - 520.40M
Total current assets 16139.73M 18803.50M 19527.30M 21922.00M 15072.30M
Long term investments 2554.20M 1254.00M 1176.10M 80.20M 21.30M
Net tangible assets - - - - 11699.10M
Short term investments 7161.75M 7021.70M 4885.30M 189.40M 381.60M
Net receivables 984.48M 1523.90M 2339.70M 7146.00M 12382.10M
Long term debt 215.20M 214.70M 191.00M 176.20M 171.60M
Inventory 110.65M 283.30M 357.70M 439.60M 502.50M
Accounts payable 534.67M 426.70M 354.00M 204.10M 160.00M
Accumulated other comprehensive income -1461.68M -1325.50M -984.60M 979.30M 1768.30M
Non currrent assets other 76.97M 36.10M 83.40M 6.50M 0.80M
Non current assets total 5839.51M 3726.20M 3479.00M 1357.10M 758.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1910.30M -2081.20M -6954.50M -35.30M -566.10M
Change to liabilities - - - - 1516.10M
Total cashflows from investing activities -2371.07M -2081.20M - - -566.10M
Net borrowings -50.90M -45.90M - - -66.70M
Total cash from financing activities -50.81M -45.90M -778.60M -1419.30M 94.20M
Net income -1091.26M -677.70M 1186.10M 12954.10M 15046.40M
Change in cash -931.17M -1901.80M -2211.40M 12182.40M 482.50M
Begin period cash flow 8603.30M 11663.70M 13875.10M 1692.70M 1210.20M
End period cash flow 7672.13M 9761.90M 11663.70M 13875.10M 1692.70M
Total cash from operating activities 438.00M 207.70M 5371.40M 13577.40M 889.70M
Issuance of capital stock - 0.00M 0.00M 110.50M 160.90M
Depreciation 367.69M 298.00M 183.40M 123.30M 75.20M
Other cashflows from investing activities - -164.60M - - -
Dividends paid - 0.00M 0.00M 484.30M 0.00M
Change to inventory 170.88M 74.50M 81.90M 62.90M -438.40M
Change to account receivables 1040.93M 387.70M 5263.84M 4369.90M -11808.10M
Sale purchase of stock 0.00M 0.00M -738.50M -986.40M 0.00M
Other cashflows from financing activities -39.96M -43.50M 0.30M 0.80M -566.10M
Change to netincome - - - - 1252.40M
Capital expenditures 168.19M 452.30M 705.50M 363.30M 154.00M
Change in working capital 516.57M 1220.60M 5574.80M 4518.50M -10730.40M
Stock based compensation 106.20M 100.90M 51.40M 108.60M 93.90M
Other non cash items 574.01M -734.10M -1275.50M -4127.10M 212.50M
Free cash flow 269.81M -244.60M 4665.90M 13214.10M 735.70M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BNTX
BioNTech SE		 -
-%		 87.51 - 7.04 9.83 1.18 2.81 32.70
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

An der Goldgrube 12, Mainz, Germany, 55131

49 6131 9084

https://www.biontech.de

7807

Name Title Year Born
Prof. Ugur Sahin M.D. Co-Founder, CEO & Chair of the Management Board 1965
Dr. Ozlem Tureci M.D. Co-Founder, Chief Medical Officer & Member of Management Board 1967
Prof. Christoph Hubert Huber M.D., Ph.D. Co-Founder & Member of Supervisory Board 1944
Mr. Jens H. Holstein CFO & Member of Management Board 1963
Dr. Sierk Poetting Ph.D. MD, COO & Member of Management Board 1973
Mr. Ryan Richardson Chief Strategy Officer, MD & Member of Management Board 1979
Mr. Sean Marett Chief Bus. Officer, Chief Commercial Officer & Member of Management Board 1965
Sylke Maas Ph.D. VP of Investor Relations and Bus. Strategy NA
Dr. James Timothy Patrick Ryan Ph.D. Sr. VP & Gen. Counsel NA
Michael Boehler MD & Head of Global External Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…